Sydney Pulsipher

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors”.

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

New England Journal of Medicine(2024)10.1056/nejmoa2403991

N/A

3.0DataRank · unranked

141 citations

Susan M. Geyer, Tyler Zemla, Michael V. Knopp, Spencer C. Behr, Sydney Pulsipher +19 more

1712P Efficacy and safety of cabozantinib (CABO) for advanced lung and thymic neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of phase III CABINET Trial (Alliance A021602)

Annals of Oncology(2025)10.1016/j.annonc.2025.08.2340

N/A

0DataRank · unranked

1 citations

T. Zemla, Susan M. Geyer, Jonathan Strosberg, Þorvarður R. Hálfdánarson, Nikolaos A. Trikalinos +13 more

Incidence and mortality indicate sex differences in chronic rhinosinusitis with nasal polyposis

The Journal of Allergy and Clinical Immunology In Practice(2025)10.1016/j.jaip.2025.05.061

N/A

0DataRank · unranked

0 citations

Alex iAkushev, Phillip Link, Kelley Dages, Benjamin Hamel, Jenny Patel +15 more